ArticleRegenerative biomaterials2026
Glucose/ROS dual-responsive mitochondria-targeting nanozyme microneedles remodel mitochondrial homeostasis to orchestrate immune metabolic reprogramming for diabetic foot ulcer healing.
Article in Regenerative biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic foot ulcers (DFUs) develop a persistent vicious loop featuring impaired mitochondrial activity and massive buildup of reactive oxygen species (ROS), accompanied by disordered immune responses; these combined pathological changes hinder the regeneration of damaged tissues. Therapeutic strategies that spatiotemporally target mitochondria to couple redox homeostasis restoration, immunometabolic reprogramming and tissue regeneration remain an unmet clinical need. Here we report a glucose/ROS dual-responsive microneedle patch incorporating mitochondria-targeting metal-phenolic nanozymes for DFU treatment. Tannic acid-cerium (TA-Ce) nano-catalysts possess strong catalytic capacities analogous to natural superoxide dismutase and catalase enzymes. These dual biomimetic functions clear excess ROS, stabilize mitochondrial physiological balance and drive macrophages to shift from pro-inflammatory M1-type toward anti-inflammatory M2 subtypes, which ultimately breaks sustained inflammatory feedback loops. Notably, the nanozyme functions dually as a therapeutic agent and a dynamic crosslinker through reversible boronate ester chemistry, allowing stable loading and microenvironment-responsive, on-demand release aligned with the pathological features of diabetic wounds. In a full-thickness diabetic rat wound model, the microneedle patch achieves 92.64% wound closure on Day 14, significantly outperforming commercial dressings. This work establishes a mitochondria-centered immunometabolic therapeutic strategy and provides a translatable platform for chronic wound regeneration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.